At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Ambrisentandrug
Likely dose
Ambrisentan 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension
In Brief
A Phase 4 clinical trial evaluating Ambrisentan for Exercise-induced Pulmonary Arterial Hypertension. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH). The investigators also want to find out if ambrisentan is safe to take without causing excessive side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedApr 2011
Primary CompletionFeb 2016
Study CompletionMay 2016
TodayJul 2026
First PostedApr 19, 2011
Enrollment StartSep 1, 2008
Primary CompletionFeb 1, 2016
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 15.2 years ago
Interventions
Ambrisentandrug
5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.